Therapeutic Efficacy of Intravenously Administered Transferrin-Conjugated Dendriplexes on Prostate Carcinomas

Abstract

This version is available at https://strathprints.strath.ac.uk/42676/ Strathprints is designed to allow users to access the research output of the University of Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Please check the manuscript for details of any other licences that may have been applied. You may not engage in further distribution of the material for any profitmaking activities or any commercial gain. You may freely distribute both the url (https://strathprints.strath.ac.uk/) and the content of this paper for research or private study, educational, or not-for-profit purposes without prior permission or charge.Any correspondence concerning this service should be sent to the Strathprints administrator: strathprints@strath.ac.ukThe Strathprints institutional repository (https://strathprints.strath.ac.uk) is a digital archive of University of Strathclyde research outputs. It has been developed to disseminate open access research outputs, expose data about those outputs, and enable the management and persistent access to Strathclyde's intellectual output. would be an attractive anti-cancer treatment strategy, however the lack of suitable carrier systems able to selectively deliver therapeutic genes to tumors has so far limited this investigation. Given that transferrin receptors are overexpressed on prostate cancer cells, the purpose of this study is to determine whether transferrinbearing dendriplex encoding TNF±, TRAIL and IL-12 would suppress the growth of prostate cancer cell lines in vitro and in vivo. TITLE Materials & Methods:Transferrin-bearing dendriplexes encoding TNF±, TRAIL and IL-12 were intravenously administered to mice bearing subcutaneous PC-3 and DU145 tumors. Results:The administration of the DAB-Tf dendriplex encoding TNF± resulted in tumor suppression for 60% of PC-3 and 50% of DU145 prostate tumors. Conclusions:These dendriplexes hold great potential as a novel approach for prostate cancer therapy. KEYWORDS 4 MATERIALS & METHODS Cell lines and reagents Preparation of transferrin-bearing polypropylenimine dendrimerGeneration 3-diaminobutyric polypropylenimine dendrimer (DAB, 24 mg) was conjugated to transferrin (Tf, 6 mg) by cross-linking with dimethylsuberimidate (DMSI, 12 mg) in triethanolamine HCl buffer (pH 7.4, 2 mL), as previously described 8 Statistical AnalysisResults were expressed as means ± standard error of the mean (S.E.M). Statistical significance was assessed by one-way analysis of variance (ANOVA) and Bonferroni multiple comparison post-test (GraphPad Prism software). P values lower than 0.05 were considered statistically different. 9 RESULTS Cellular uptake of DNAConfocal microscopy experiments confirmed that Cy3-labelled DNA was taken up by PC-3, DU145 and LNCaP cells (Figure 1). The fluorescently-labeled DNA was found to be disseminated in the cytoplasm following treatment with DAB-Tf and DAB dendriplexes in the three teste...

Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment

“…In addition, we found that the efficacy could be further improved by targeting the liposomes to tumour cells using transferrin. 41 Liposome-mediated drug delivery avoided the docetaxel-associated toxicities that we previously observed. Future clinical study does not necessarily involve liposomes as both drugs are extensively used clinically, and the relative dosing of the two agents can be tested easily.…”

TRAIL-based gene delivery and therapeutic strategies

“…The PAMAM-PEG-Angiopep/pORF-TRAIL NPs could penetrate the blood-brain barrier (BBB) and target glial cells based on Angiopep-2-mediated delivery, with hight transfection efficiency. Another strategy has been reported in which transferrin (Tf) was conjugated to a generation 3 diaminobutyric polypropylenimine (DAB) dendrimer; this delivery system harbors plasmids encoding for TNF-α, TRAIL, or IL-12 and leads to therapeutic effects on prostate tumors following intravenous administration [63]. In addition, lactoferrin (Lf)-bearing DAB dendriplexes showed similar efficacy [64].…”

Dendrimer-based nanoparticles in cancer chemotherapy and gene therapy

“…Antibody anti-CD71-modified PA-MAM dendrimer shows much higher cellular uptake and more efficient antiapoptotic gene silencing in prostate cancer cells compared to no-antibody ones [162]. Transferrin-conjugated dendrimers can highly express tumor necrosis factor α (TNFα) by delivery of plasmids in prostate cancer cells in vitro and in vivo [163]. Major histocompatibility complex (MHC) class II-targeting peptides modified dendrimers can deliver DNA-based vaccines to specifically accumulate in professional antigen-presenting cells, which enhances immunostimulatory potency and provides an immunotherapy for tumor treatment [164].…”